Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Exelixis Inc. (EXEL) shares declined over 12% following the release of detailed STELLAR-303 Phase 3 trial results for zanzalintinib plus Tecentriq in metastatic colorectal cancer. Although the study achieved one dual primary endpoint with a 20% reduction in the risk of death and improved overall survival (median 10.9 months vs. 9.4 months for regorafenib), the inability to claim statistical superiority for progression-free survival due to the prespecified hierarchical testing strategy likely contributed to the negative market reaction.

Analysis

Exelixis Inc. (EXEL) shares experienced a significant decline of 12.17% to $34.47 following the release of detailed STELLAR-303 Phase 3 trial results for zanzalintinib in combination with Tecentriq. This negative market reaction occurred despite the trial successfully meeting one of its dual primary endpoints, demonstrating a 20% reduction in the risk of death in the intention-to-treat (ITT) population for metastatic colorectal cancer.

The combination therapy showed a median overall survival (OS) of 10.9 months compared to 9.4 months for regorafenib, with OS benefits consistently observed across prespecified subgroups. Landmark OS estimates further supported this, showing 46% vs. 38% at 12 months and 20% vs. 10% at 24 months for the combination versus regorafenib, respectively. However, overall survival data for patients without liver metastases (NLM) remains immature, with a final analysis pending.

A critical factor contributing to the stock's downturn appears to be the inability to claim statistical superiority for progression-free survival (PFS) despite a trend for improvement. This limitation stems from the prespecified hierarchical testing strategy, which likely disappointed investors expecting a clearer win across both primary endpoints. The market's moderately negative sentiment (score -0.5) and the specific -0.6 sentiment for EXEL underscore this concern.

Key Decisions for Investors

• Monitor the upcoming final analysis for overall survival in non-liver metastases patients, as this could provide further clarity on the drug's broader efficacy profile.
• Assess the long-term commercial implications of the zanzalintinib combination, considering the mixed trial results where OS improved but statistical superiority for PFS could not be claimed.
• Evaluate competitor pipelines and market positioning within the metastatic colorectal cancer space, as the nuanced trial outcome may impact Exelixis's competitive advantage.